$$A_0 \hbox{-} A_1 \hbox{-} A_2 \hbox{-} A_3 \hbox{-} A_4 \hbox{-} A_5 \hbox{-} A_6 \hbox{-} A_7 \hbox{-} A_8 \hbox{-} A_9 \hbox{-} A_{10} \ (I)$$

or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein:

A₀ is an acyl group selected from:

(1) R-(CH₂)_n-C(O)-; wherein n is an integer from 0 to 8 and F selected from hydroxyl; methyl; N-acetylamino; methoxyl carboxyl; eyclobeyyl optionally acceptable.

(1) R-(CH₂)_n-C(O)-; wherein n is an integer from 0 to 8 and R is selected from hydroxyl; methyl; N-acetylamino; methoxyl; carboxyl; cyclohexyl optionally containing one or two double bonds and optionally substituted with one to three hydroxyl groups; and a 5- or 6-membered aromatic or nonaromatic ring optionally containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring is optionally substituted with a moiety selected from alkyl, alkoxy, and halogen;

IN THE CLAIMS

Please replace claims 1 and 12 with the following correspondingly numbered claims:

1 (Twice Amended). A compound of the formula:

A₀-A₁-A₂-A₃-A₃-A₅-A₆-A₇-A₈-A₉-A₁₀

or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein: A_0 is an acyl group selected from:

(1) R-(CH₂)_n-C(O)-; wherein n is an integer from 0 to 8 and R is selected from hydroxyl; methyl; N-acetylamino; methoxyl; carboxyl; cyclohexyl optionally containing one or two double bonds and optionally substituted with one to three hydroxyl groups; and a 5- or 6-membered aromatic or nonaromatic ring optionally containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring is optionally substituted with a moiety selected from alkyl, alkoxy, and halogen; and